0 CHECKOUT

Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review

  • ID: 1292009
  • March 2016
  • 81 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Eisai Co., Ltd.
  • Genta Incorporated
  • Merck & Co., Inc.
  • Shire Plc
  • MORE

Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Eisai Co., Ltd.
  • Genta Incorporated
  • Merck & Co., Inc.
  • Shire Plc
  • MORE

List of Tables

List of Figures

Section 1 - About the Company

Celgene Corporation - Key Facts

Celgene Corporation - Key Employees

Celgene Corporation - Key Employee Biographies

Celgene Corporation - Major Products and Services

Celgene Corporation - Pharmaceutical Pipeline Products Data

Celgene Corporation, Pipeline Products by Therapy Area

Celgene Corporation, Pipeline Products by Development Phase

Celgene Corporation - History

Celgene Corporation - Company Statement

Celgene Corporation - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Celgene Corporation - Business Description

Celgene Corporation - Corporate Strategy

Celgene Corporation - SWOT Analysis

SWOT Analysis - Overview

Celgene Corporation - Strengths

Strength - Increased Product Sales Drives Revenue

Strength - Focused Research and Development Activities

Strength - Strong Presence - Multiple Myeloma Market

Celgene Corporation - Weaknesses

Weakness - Imnovid - Birth Defects Risks

Weakness - Decline in Vidaza and Thalomid

Celgene Corporation - Opportunities

Opportunity - Product Approvals and Launches

Opportunity - Late Stage Development Pipeline

Opportunity - Business Initiatives

Celgene Corporation - Threats

Threat - Litigations and Legal Issues

Threat - Highly Competitive Industry

Threat - Stringent Government Regulations

Celgene Corporation - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Celgene Corporation, Recent Deals Summary

Section 5 – Company’s Recent Developments

Feb 11, 2016: Celgene Elects Mark Alles and Jacqualyn Fouse PhD to its Board of Directors

Feb 10, 2016: Celgene Expands Relationship with Medidata in Enterprise Clinical Trial Technology

Jan 28, 2016: Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results

Jan 11, 2016: Organizational Changes Strengthen Leadership Team and Position Celgene for Long-Term Growth

Jan 11, 2016: Celgene Announces 2016 Financial Outlook and Preliminary 2015 Results

Jan 11, 2016: Celgene Corporation Announces 2016 Financial Outlook and Preliminary 2015 Results

Jan 11, 2016: Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer

Jan 05, 2016: OncoMed Achieves $72.5 Million in Milestone Payments From Celgene; Announces Year-End Cash Balance

Nov 05, 2015: Celgene Reports Third Quarter 2015 Operating and Financial Results

Oct 16, 2015: Celgene And Mesoblast Extend Agreement

Section 6 – Appendix

Methodology

Ratio Definitions

About us

Contact Us

Disclaimer

List of Tables

Celgene Corporation, Key Facts

Celgene Corporation, Key Employees

Celgene Corporation, Key Employee Biographies

Celgene Corporation, Major Products and Services

Celgene Corporation, Number of Pipeline Products by Therapy Area

Celgene Corporation, Number of Pipeline Products by Development Stage

Celgene Corporation, Pipeline Products By Therapy Area and Development Phase

Celgene Corporation, History

Celgene Corporation, Other Locations

Celgene Corporation, Subsidiaries

Celgene Corporation, Key Competitors

Celgene Corporation, Ratios based on current share price

Celgene Corporation, Annual Ratios

Celgene Corporation, Interim Ratios

Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Celgene Corporation, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

Celgene Corporation, Pipeline Products by Therapy Area

Celgene Corporation, Pipeline Products by Development Phase

Celgene Corporation, Performance Chart (2011 - 2015)

Celgene Corporation, Ratio Charts

Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Celgene Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Note: Product cover images may vary from those shown
3 of 4

Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited
Amgen Inc.
Shire Plc
Pharmaceutical Product Development, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Genta Incorporated

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.